Evexia Diagnostics adds at-home blood collection kit Biobox to its platform

Evexia Diagnostics has added Biobox by Access Labs to its platform, giving clinicians an at-home blood collection option that can help reduce testing barriers for remote and busy patients. The rollout is aimed at improving patient completion rates while expanding access to more than 25 functional and hormone-focused testing panels.

Why it matters: - Biobox gives clinicians a new at-home blood collection option that can make diagnostic testing easier for patients who avoid in-office draws. - The kit is designed to improve patient completion rates, expand access for telehealth and geographically dispersed patients, and simplify diagnostic workflows. - Evexia Diagnostics is positioning the addition as part of a broader push toward more convenient, access-focused care.

What happened: - Evexia Diagnostics announced the availability of Biobox by Access Labs on the Evexia Diagnostics platform. - The at-home testing option is now available for ordering through the platform. - The announcement was made June 30, 2026. - Biobox lets patients collect an upper-arm capillary blood sample at home and return it for laboratory analysis without visiting a draw center or physician’s office.

The details: - Biobox uses a “Click. Collect. Send.” workflow. - The collection process requires less than 1 mL of blood. - Laboratory results are available within 24 to 48 hours after sample receipt. - The kit includes direct-to-patient fulfillment and return shipping. - Evexia clinicians can use Biobox with more than 25 available testing panels. - The available panels cover functional health and hormone management areas including hormone optimization, metabolic wellness, thyroid evaluation, weight management, and cardiovascular health. - Access Labs data cited in the release says nearly 70% of patients are unwilling to travel more than 10 miles from home for a blood test. - Ryan L. Obermeier, chief commercial officer of Evexia Diagnostics, said Biobox helps remove logistical barriers that prevent patients from completing recommended testing.

Between the lines: - The move reflects a larger shift in healthcare toward home-based and remote testing models. - Biobox appears aimed at practices that need a practical option for patients who are hard to reach through traditional lab workflows. - The platform expansion also reinforces Evexia Diagnostics’ focus on functional and integrative healthcare practitioners. - Access Labs says Biobox is designed to maintain clinical-grade quality and accuracy while improving convenience.

What's next: - Evexia Diagnostics is likely to promote Biobox as a tool for improving test completion and expanding the reach of its platform. - Adoption will depend on whether clinicians see meaningful gains in convenience, turnaround time, and patient adherence. - The company says the addition aligns with its mission to help practitioners deliver advanced diagnostics where patients are.

The bottom line: - Evexia Diagnostics is betting that at-home blood collection can remove one of the biggest frictions in diagnostic testing: getting patients to actually complete the test.